Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension

Yuichi Tamura; Asuka Furukawa; Yudai Tamura; Kenta Yamada; Hirohisa Taniguchi; Keiichi Fukuda; Akio Kawamura; Toru Satoh

doi:10.1002/pul2.12058

Long-term safety of a structured transition protocol from parenteral prostanoids to selexipag in pulmonary arterial hypertension

Pulm Circ. 2022 Mar 17;12(1):e12058. doi: 10.1002/pul2.12058. eCollection 2022 Jan.

Authors

Yuichi Tamura^{1

2}, Asuka Furukawa^{1

2}, Yudai Tamura², Kenta Yamada², Hirohisa Taniguchi², Keiichi Fukuda³, Akio Kawamura², Toru Satoh⁴

Affiliations

¹ Pulmonary Hypertension Center International University of Health and Welfare Mita Hospital Tokyo Japan.
² Department of Cardiology International University of Health and Welfare School of Medicine Narita Japan.
³ Department of Cardiology Keio University School of Medicine Tokyo Japan.
⁴ Department of Cardiology Kyorin University School of Medicine Tokyo Japan.

Abstract

There was no structured method for safely transition from parenteral prostanoids to oral medication. We enrolled 37 idiopathic/hereditary pulmonary arterial hypertension patients receiving triple combination therapy including parenteral prostanoids into structured transition program to oral selexipag. Four (10.8%) patients successfully transitioned under the protocol, and all of them presented long-term safety.

Keywords: prostanoids; pulmonary arterial hypertension; transition therapy.